The Anesthesia Reckoning: Six Predictions for 2026

What comes after denial, delay, and avoidance

I’ve lost count of how many conversations this year have started the same way. A leader leans back, exhales, and says, “This market is brutal.” It’s the healthcare equivalent of walking into a burning building and acting surprised that it’s warm.

They’re not wrong. Workforce shortages remain real. Reimbursement pressure hasn’t eased. Payers still see anesthesia as a cost center to compress, not a capability to protect. And the No Surprises Act continues to do what poorly designed policy usually does: distort behavior while claiming neutrality.

But difficulty doesn’t remove responsibility. And markets don’t owe us relief.

As we move toward 2026, I don’t think anesthesia is headed for recovery in the way many leaders hope. I think it’s headed for something more clarifying.

A sorting.

Over the past year, the same signals have surfaced again and again across staffing models, leadership conversations, ASC strategy, hospital decision-making, and private equity boardrooms. If those signals hold, 2026 won’t feel worse. It will feel more honest.

Here’s what that honesty is likely to reveal.

1. The market won’t recover. It will sort.

Time and again, when I talk with anesthesia business operators, I hear the same refrain: we just need to wait this market out.

They couldn’t be more wrong.

Waiting assumes the market is a storm that will pass. It isn’t. It’s a climate shift. Organizations built for the old climate don’t get relief. They get exposed.

By 2026, the gap between stable and fragile groups will be unmistakable. Not because external conditions improved for some and not others, but because internal decisions compounded.

A small number of organizations will show predictable staffing, disciplined contracts, and leaders who actually know their sites. A much larger number will still be scrambling, still blaming the market, still waiting for conditions to normalize.

The difference won’t be clinical skill or size. It will be leadership density, operating discipline, and the willingness to say no. No to bad contracts. No to unsustainable growth. No to the fiction that every site must be saved.

By 2026, the question won’t be who survived the market. It will be who stopped pretending it was temporary.

2. ASCs will expose hospital-era thinking

Surgical volume migration isn’t new. What’s new is how little patience ASCs have for inherited habits.

Many anesthesia groups are still trying to run ambulatory centers with hospital-era assumptions. Staffing by tradition. Clinician time allocated by precedent. Leadership defined by title rather than impact. That model is already cracking.

By 2026, the groups that win in ASCs will look different. They’ll design staffing models for throughput and predictability. They’ll treat clinician time as a strategic input. And they’ll put their best operators, not their most senior names, in charge.

ASCs don’t reward effort or loyalty. They reward fit. And they are remarkably efficient at revealing who actually understands how anesthesia creates value outside the hospital.

3. Workforce pressure becomes a leadership test

The clinician shortage isn’t going away in 2026. What will change is how uneven its impact becomes.

Some sites will stabilize despite paying roughly the same as their peers. Others will continue hemorrhaging talent while offering ever-richer incentives. The difference won’t be generosity. It will be leadership presence and clarity.

Teams stay where expectations are clear, schedules are fair, leaders are visible, and bad behavior is addressed early. They leave when dysfunction is tolerated and accountability is abstract.

By 2026, it will be hard to keep calling this a recruiting problem. Same labor pool. Same credentials. Radically different outcomes.

There’s another signal forming beneath the surface.

We are firmly in the expansion phase of nurse anesthesia education. There are roughly 150 nurse anesthesia programs in the U.S., with another 15 to 17 programs in some stage of capability review. Virtually all legacy programs are also increasing cohort sizes.

This doesn’t mean oversupply in 2026. We’re nowhere near that. But it does mean the trajectory is changing. About 3,200 CRNA graduates entered the market in 2025, with projections closer to 3,600 in 2026, and further expansion likely beyond that.

The implication isn’t relief. It’s exposure.

As the pipeline grows, organizations that relied on scarcity to mask weak leadership, poor onboarding, or dysfunctional culture will feel pressure sooner than they expect. More graduates won’t save broken systems. They’ll stress-test them.

4. Hospitals will cool on insourcing—and rediscover efficiency

Over the last 18 months, a number of hospitals and health systems terminated third-party anesthesia contracts and chose to insource. The logic sounded compelling at the time. More control. Lower cost. Fewer intermediaries.

What many discovered instead was complexity, operational risk, and financial exposure that didn’t behave the way the models promised.

Hospitals insourcing anesthesia is a lot like me deciding to fix my own plumbing because I watched a YouTube video. It starts with unearned confidence and ends with raw sewage.

By 2026, more hospitals will quietly acknowledge that insourcing anesthesia was a strategic miscalculation. Some already are. A growing number are returning to outsourced models or actively exploring them again, having learned that running anesthesia at scale requires far more than payroll and good intentions.

Insourcing didn’t fail because anesthesia companies are perfect. It failed because anesthesia is operationally unforgiving. Workforce volatility, coverage guarantees, compliance, recruitment, and clinician alignment don’t become simpler just because ownership changes.

At the same time, hospitals are waking up to something else.

They are finally getting serious about perioperative efficiency. Blank checks paired with poorly run ORs are proving far more expensive over time than disciplined throughput, block utilization, staffing design, and accountability.

By 2026, the hospitals that succeed won’t be the ones who tried to do everything themselves. They’ll be the ones who demanded efficiency and partnered accordingly.

Control without competence turned out to be a costly illusion.

5. Large and regional anesthesia groups will be forced to prove their stories

Over the next 12 to 24 months, at least one of the largest anesthesia platforms will make a credible move toward an IPO window, likely in 2026 or early 2027. Whether that window stays open is another question entirely. I remain skeptical.

Public markets don’t underwrite hope. They underwrite repeatability.

It’s worth saying plainly: there remains a shockingly large number of poorly run regional anesthesia groups in this country.

That reality cuts two ways. Hospitals are increasingly losing patients under legacy groups plagued by inconsistent coverage, OR delays, surgeon frustration, and chronic inefficiency. Referral patterns shift. Volumes leak. Administrators notice.

At the same time, it means high-performing regional and national platforms still have real organic growth opportunity. Not because the market is expanding, but because competence remains unevenly distributed.

By 2026, growth will continue to come less from acquisition and more from displacement. Hospitals aren’t looking for bigger anesthesia partners. They’re looking for better ones.

Platforms that can’t demonstrate durable staffing models, rational contract portfolios, and consistent site-level performance will find themselves in big trouble.

Private equity’s first act rewarded scale. The next act will demand operational excellence.

6. Leadership avoidance becomes the most expensive line item

Burnout will remain the headline diagnosis. Leadership avoidance will remain the underlying disease.

Weak chiefs who never get coached or replaced. Medical directors who are effectively the ‘Mayor of the Hospital Parking Lot’ — great at waving but terrible at governing. Chronic dysfunction that everyone sees and no one addresses. These aren’t soft issues. They’re balance-sheet problems.

By 2026, the cost of avoidance will be easier to see. Premium labor. Turnover. Lost contracts. Cultural drift that no engagement survey can fix.

The groups that stabilize won’t be nicer. They’ll be earlier. Earlier to confront issues. Earlier to make changes. Earlier to accept short-term discomfort in exchange for long-term coherence.

What this really means

None of these predictions require a worse market. They simply require the current one to continue.

That’s what makes 2026 interesting.

It won’t punish anesthesia. It will stop protecting us from our own decisions. Some organizations will discover that honesty attracts capital. Others will learn that transparency accelerates reckoning.

Honesty is coming either way. The only real choice is whether to meet it deliberately or be exposed by it.